Mineralys Therapeutics (MLYS) vs Palvella Therapeutics (PVLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Palvella Therapeutics (PVLA) has outperformed Mineralys Therapeutics (MLYS) over the past year, gaining 75.5% versus a loss of 40.3%. Mineralys Therapeutics is the larger company by market cap ($2.00 billion vs $1.92 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MLYS | PVLA |
|---|---|---|
| Share price | $22.62 | $133.30 |
| Market cap | $2.00B | $1.92B |
| 1-day change | +1.05% | +1.49% |
| YTD return | -38.33% | +25.48% |
| 1-year return | -40.30% | +75.47% |
| 5-year return | — | -63.60% |
| EPS (TTM) | $-4.22 | $-4.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-154.65M | $-41.72M |
| 52-week high | $47.65 | $161.38 |
| 52-week low | $21.46 | $65.93 |
| Distance from 52-week high | -52.54% | -17.40% |
| Analyst consensus | none | none |
| Avg. price target upside | +114.46% | +72.95% |
| Average volume | 1.04M | 211.36K |
| Shares outstanding | 88.41M | 14.41M |
| Employees | 76 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PVLA has outperformed MLYS by 115.8 percentage points over the past year.
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
About Palvella Therapeutics
PVLA stock →Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
MLYS vs PVLA FAQ
Which is bigger, Mineralys Therapeutics or Palvella Therapeutics?
Mineralys Therapeutics (MLYS) is larger, with a market capitalization of $2.00B compared with $1.92B for Palvella Therapeutics (PVLA).
Which stock has performed better over the past year, MLYS or PVLA?
PVLA returned +75.47% over the past 12 months, compared with -40.30% for MLYS (price return, excluding dividends). Past performance does not predict future results.
Are Mineralys Therapeutics and Palvella Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.